Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment

Publisher： Karger

E-ISSN： 1423-0232|79|1-2|78-84

ISSN： 0030-2414

Source： Oncology, Vol.79, Iss.1-2, 2010-11, pp. : 78-84

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prognosis in Patients with Non-Small Cell Lung Cancer Who Received Erlotinib Treatment and Subsequent Dose Reduction due to Skin Rash

By  

Oncology Research and Treatment, Vol. 35, Iss. 12, 2012-11 ,pp. : 747-752

Karger

Access to resources Recommend Favorite

Gender Differences in Treatment Outcomes among Patients with Non-Small Cell Lung Cancer Given a Combination of Carboplatin and Paclitaxel

By  

Oncology, Vol. 75, Iss. 3-4, 2008-10 ,pp. : 169-174

Karger

Access to resources Recommend Favorite

Erlotinib versus Pemetrexed for Pretreated Non-Squamous Non-Small Cell Lung Cancer Patients in Clinical Practice

By  

Oncology, Vol. 84, Iss. 5, 2013-02 ,pp. : 255-264

Karger

Access to resources Recommend Favorite

Vinorelbine-Based Regimens as Salvage Treatment in Patients with Advanced Non-Small Cell Lung Cancer: Two Parallel Multicenter Phase II Trials

By  

Oncology, Vol. 60, Iss. 3, 2001-04 ,pp. : 235-241

Karger

Access to resources Recommend Favorite

Erlotinib after Failure of Gefitinib Treatment of More Than 6 Months in Advanced Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 1-2, 2012-01 ,pp. : 8-9

Karger

Access to resources Recommend Favorite